Determination of α-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid

Peritoneal Dialysis International

Volumn 23, Issue 2, 2003, Pages 146-150

  Anderstam, Björn ^a   García López, Elvia ^a   Heimbürger, Olof ^a   Lindholm, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Icodextrin; Maltose; Oligosaccharides; Polyglucose; Renal failure; Amylase

Indexed keywords

4 NITROPHENOL; AMYLASE; GLUCOSE; ICODEXTRIN; PANCREAS ENZYME; PERITONEAL DIALYSIS FLUID; POLYSACCHARIDE; REAGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DIALYSATE LEVEL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE; FEMALE; HUMAN; MALE; METABOLITE; PRIORITY JOURNAL; SAMPLE; STATISTICAL ANALYSIS;

EID: 0037355887     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080302300209     Document Type: Article

References (13)

1. Mistry CD. Glucose polymer as an osmotic agent in continuous peritoneal dialysis [Thesis]. London: University of London, 1989.
2. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46:496-503.
3. Posthuma N, ter Wee PM, Donker AJ, Oe PL, van Dorp W, Peers EM, et al. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. Perit Dial Int 1997; 17:602-7.
4. Mistry CD, Gokal R. Single daily overnight (12-h dwell) use of 7.5% glucose polymer (Mw 18700; Mn 7300) +0.35% glucose solution: a 3-month study. Nephrol Dial Transplant 1993; 8:443-7.
5. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001; 21:275-81.
6. Schoenicke G, Grabensee B, Plum J. Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity. Nephrol Dial Transplant 2002; 17:1988-92.
7. Grzegorzewska AE, Antczak-Jedrzejczak D, Mariak I. Polyglucose dialysis solution influences serum activity of amylase and of lipase differently. Adv Perit Dial 2000; 16:113-18.
8. Plum J, Gentile S, Verger C, Brunkhorst R, Bahner U, Faller B, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39:862-71.
9. Bajo MA, Selgas R, Hevia C, Castro MJ, Aquilera A, Millan I, et al. Icodextrin 7.5% dialysate for diurnal exchange in patients treated with CCPD [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S49.
10. Wang R, Moberly JB, Martis L, Turner P, Leesch V. Kinetic analysis of icodextrin interference with serum amylase activity assays [Abstract]. Perit Dial Int 2002; 22(Suppl 1):S17.
11. de Waart DR, Zweers MM, Struijk DG, Krediet RT. Icodextrin degradation products in spent dialysate of CAPD patients and the rat, and its relation with dialysate osmolality. Perit Dial Int 2001; 21:269-74.
12. Stryer L. Biochemistry. 3rd ed. New York: W.H. Freeman; 1988.
13. Bastani B, Mifflin TE, Lovell MA, Bowden JH, Bruns DE. Serum total amylase, pancreatic iso-amylase and lipase activity in chronic renal failure patients on peritoneal dialysis, hemodialysis or no dialysis. Adv Perit Dial 1986; 2:77-80.